4.8 Article

Effect of cholesterol on the molecular structure and transitions in a clinical-grade lung surfactant extract

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1701239114

Keywords

lung surfactant; cholesterol; order parameter; solid-state NMR; dipolar recoupling

Funding

  1. Swedish Foundation for Strategic Research
  2. Swedish Research Council
  3. Linnaeus Center of Excellence Organizing molecular matter
  4. Deutsche Forschungsgemeinschaft (DFG) [ME 4475/1-1]
  5. Knut and Alice Wallenberg Foundation

Ask authors/readers for more resources

The lipid-protein film covering the interface of the lung alveolar in mammals is vital for proper lung function and its deficiency is related to a range of diseases. Here we present a molecular-level characterization of a clinical-grade porcine lung surfactant extract using a multitechnique approach consisting of H-1-C-13 solid-state nuclear magnetic spectroscopy, small-and wide-angle X-ray scattering, and mass spectrometry. The detailed characterization presented for reconstituted membranes of a lung extract demonstrates that the molecular structure of lung surfactant strongly depends on the concentration of cholesterol. If cholesterol makes up about 11% of the total dry weight of lung surfactant, the surfactant extract adopts a single liquid-ordered lamellar phase, L-alpha(o), at physiological temperatures. This L-alpha(o) phase gradually changes into a liquid-disordered lamellar phase, L-alpha(d), when the temperature is increased by a few degrees. In the absence of cholesterol the system segregates into one lamellar gel phase and one L-alpha(d) phase. Remarkably, it was possible to measure a large set of order parameter magnitudes vertical bar S-CH vertical bar from the liquid-disordered and - ordered lamellar phases and assign them to specific C-H bonds of the phospholipids in the biological extract with no use of isotopic labeling. These findings with molecular details on lung surfactant mixtures together with the presented NMR methodology may guide further development of pulmonary surfactant pharmaceuticals that better mimic the physiological self-assembly compositions for treatment of pathological states such as respiratory distress syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available